Evaluating the efficacy and safety of Danning Pian in the short-term treatment of patients with non-alcoholic fatty liver disease: A multicenter clinical trial

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 3, 2004, Pages 375-380

  Fan, Jian Gao ^a   Liu, Hou Yu ^b   Yuan, Yao Zong ^c   Cai, Xiong ^d   Chen, Wei Xiong ^e   Liu, Hai Lin ^f   Wang, Jun Rong ^g   Meng, Xiang Jun ^h   Bai, Nai Yun ⁱ   Xu, Zhen Ping ^j  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Zhongshang Hospital   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e Sixth Municipal Hospital of Shanghai   (China)

^f Shanghai Municipal Hospital   (China)

^g Shanghai Putuo District Central Hospital   (China)

^h Changning District Central Hospital   (China)

ⁱ Zhabei District Central Hospital   (China)

^j Department of Gastroenterology   (China)

more..

Author keywords

Chinese herbal medicine; Danning Pian; Fatty liver; Non alcoholic; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; BILIRUBIN GLUCURONIDE; CHINESE DRUG; CHOLESTEROL; DANNING PIAN; GAMMA GLUTAMYLTRANSFERASE; LIPID; LIVER ENZYME; PLANT MEDICINAL PRODUCT; RHUBARB EXTRACT; SUGAR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VITAMIN B GROUP; YIGANLING PIAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; HUMAN; LABORATORY TEST; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONALCOHOLIC FATTY LIVER; PHYSICAL EXAMINATION; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TABLET FORMULATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; ALANINE TRANSAMINASE; CITRUS SINENSIS; DRUGS, CHINESE HERBAL; FATTY LIVER; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; POLYGONUM; RHEUM; TREATMENT OUTCOME;

EID: 4444219645     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Tagle Arrospide M. Non-alcoholic fatty liver. Rev Gastroenterol Peru 2003;23:49-57.
2. Alba LM, Lindor K. Non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003;17:977-986.
3. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002;17:S186-S190.
4. Gronbaek H, Eivindson MV, Hamilton-Dutoit S, Vilstrup H. Nonalcoholic steatohepatitis-a "new" hepatic disease. Ugeskr Laeger 2003;165:1115-1118.
5. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002;17:1136-1143.
6. Alvarez-Martinez H, Perez-Campos E, Non-alcoholic steatohepatitis. Rev Gastroenterol Mex 2002;67:118-125.
7. Linhart HG. Non-alcoholic steatohepatitis. Schweiz Rundsch Med Prax 2000;89:963-966.
8. de Knegt RJ. Non-alcoholic steatohepatitis: clinical significance and pathogenesis. Scand J Gastroenterol Suppl 2001;234:88-92.
9. Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pharmacother 2003;4:611-623.
10. Hookman P, Barkin JS. Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach. Am J Gastroenterol 2003;98:495-499.
11. Sanyal AJ. Treatment of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002;17:385-388.
12. Oneta CM, Dufour JF. Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Med Wkly 2002;132:493-505.
13. Angulo P, Lindor KD. Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:797-810.
14. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001;21:81-88.
15. Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep 2002;4:37-44.
16. Kobak GE, Deutsch G, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Fat-laden hepatocytes are more prone to cellular necrosis than apoptosis when exposed to hydrophobic bile acids. Gastroenterology Suppl 2002;122:642.
17. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996;23:1464-1467.
18. Pasha T, Heathcote J, Gabriel S, Cauch-Dudek K, Jorgensen R, Therneau T, et al. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999;29: 21-26.
19. Zhu PT, Zhang JZ, Wang YS, Gao J. Treatment of chronic biliary tract infection and gallstone diseases with Dan Ning Tab, Hitrechol and UDCA (A comparative clinical trial). Zhongguo Zhongxiyi Jiehe Waike Zazhi 1995;4:205-209.
20. Fatty Liver and Alcoholic Liver Disease Study Group of Chinese Liver Disease Association. Diagnostic criteria of nonalcoholic fatty liver disease. Zhonghua Ganzangbing Zazhi 2003;11:71.
21. Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003;9:1106-1110.
22. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-669.
23. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-1493.
24. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.
25. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
26. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362.
27. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
28. Angulo P, Lindor KD. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001;120:1281-1285.
29. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
30. Cotrim HP, Parana R, Braga E, Lyra L. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 2000;95:3018-3019.
31. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714-1719.
32. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
33. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-1493.
34. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123.
35. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-1219.
36. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999;353:1634-1636.
37. Fan JG, Zhong L, Wang GL, Tian L, Wu W, Li M. Influence of ursodeoxycholic acid on the therapeutic effects of low-calorie diet in obesity and hyperlipidemia rats with steatohepatitis. Zhonghua Ganzangbing Zazhi 2002;10:43-45.